Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
Sarcomas are rare but highly aggressive mesenchymal tumors with a median survival of 10–18 months for metastatic disease. Mutation and/or overexpression of many receptor tyrosine kinases (RTKs) including c-Met, PDGFR, c-Kit and IGF1-R drive defective signaling pathways in sarcomas. MGCD516 (Sitravat...
Main Authors: | , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826192/ |